questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Molécules d'interaction stromale
Molécules d'interaction stromale : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Biopsie
Immunohistochimie
Marqueurs tumoraux
Tumeurs
Imagerie par résonance magnétique
Interactions cellulaires
Biopsie
Analyse histologique
Symptômes
5
Croissance tumorale
Symptômes
Tumeurs
Environnement tumoral
Symptômes précoces
Symptômes tardifs
Traitement
Réversibilité des symptômes
Prévention
5
Prévention
Facteurs de risque
Mode de vie sain
Prévention des tumeurs
Dépistage
Détection précoce
Éducation sur le cancer
Sensibilisation
Vaccins
Prévention du cancer
Traitements
5
Thérapies ciblées
Immunothérapie
Efficacité des traitements
Tumeurs
Effets secondaires
Réactions immunitaires
Médecine personnalisée
Profil moléculaire
Thérapies combinées
Efficacité des traitements
Complications
5
Progression tumorale
Complications
Gestion des complications
Suivi médical
Prévisibilité
Interactions tumorales
Qualité de vie
Complications
Facteurs de risque
5
Facteurs de risque
Inflammation chronique
Alimentation
Antioxydants
Antécédents familiaux
Prédisposition génétique
Toxines
Exposition environnementale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Molécules d'interaction stromale : Questions médicales les plus fréquentes",
"headline": "Molécules d'interaction stromale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Molécules d'interaction stromale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Molécules d'interaction stromale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines membranaires",
"url": "https://questionsmedicales.fr/mesh/D008565",
"about": {
"@type": "MedicalCondition",
"name": "Protéines membranaires",
"code": {
"@type": "MedicalCode",
"code": "D008565",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Molécule-1 d'interaction stromale",
"alternateName": "Stromal Interaction Molecule 1",
"url": "https://questionsmedicales.fr/mesh/D000071737",
"about": {
"@type": "MedicalCondition",
"name": "Molécule-1 d'interaction stromale",
"code": {
"@type": "MedicalCode",
"code": "D000071737",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.875.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Molécule-2 d'interaction stromale",
"alternateName": "Stromal Interaction Molecule 2",
"url": "https://questionsmedicales.fr/mesh/D000071738",
"about": {
"@type": "MedicalCondition",
"name": "Molécule-2 d'interaction stromale",
"code": {
"@type": "MedicalCode",
"code": "D000071738",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.875.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Molécules d'interaction stromale",
"alternateName": "Stromal Interaction Molecules",
"code": {
"@type": "MedicalCode",
"code": "D000071736",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Peter B Stathopulos",
"url": "https://questionsmedicales.fr/author/Peter%20B%20Stathopulos",
"affiliation": {
"@type": "Organization",
"name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca."
}
},
{
"@type": "Person",
"name": "Paul Sohn",
"url": "https://questionsmedicales.fr/author/Paul%20Sohn",
"affiliation": {
"@type": "Organization",
"name": "Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN."
}
},
{
"@type": "Person",
"name": "Wenting Wu",
"url": "https://questionsmedicales.fr/author/Wenting%20Wu",
"affiliation": {
"@type": "Organization",
"name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN."
}
},
{
"@type": "Person",
"name": "Marjan Slak Rupnik",
"url": "https://questionsmedicales.fr/author/Marjan%20Slak%20Rupnik",
"affiliation": {
"@type": "Organization",
"name": "Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Chih-Chun Lee",
"url": "https://questionsmedicales.fr/author/Chih-Chun%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Impact of formulation design and lyophilisation on the physicochemical characteristics of finasteride nanosystems.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36749573",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/02652048.2023.2178537"
}
},
{
"@type": "ScholarlyArticle",
"name": "A prospective evaluation of the effect of finasteride on prostate health index (phi).",
"datePublished": "2023-03-01",
"url": "https://questionsmedicales.fr/article/36856925",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11255-023-03530-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.",
"datePublished": "2022-08-15",
"url": "https://questionsmedicales.fr/article/35920739",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09546634.2022.2109567"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair.",
"datePublished": "2023-06-28",
"url": "https://questionsmedicales.fr/article/37385468",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cca.2023.117456"
}
},
{
"@type": "ScholarlyArticle",
"name": "Physicochemical Characterization of Chitosan-Decorated Finasteride Solid Lipid Nanoparticles for Skin Drug Delivery.",
"datePublished": "2022-08-06",
"url": "https://questionsmedicales.fr/article/35971450",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/7792180"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Molécules d'interaction stromale",
"item": "https://questionsmedicales.fr/mesh/D000071736"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Molécules d'interaction stromale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Molécules d'interaction stromale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Molécules d'interaction stromale",
"description": "Comment diagnostiquer une interaction stromale ?\nQuels tests sont utilisés pour les molécules stromales ?\nLes marqueurs stromaux sont-ils spécifiques ?\nPeut-on détecter les molécules stromales par imagerie ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Finasteride#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Molécules d'interaction stromale",
"description": "Quels symptômes sont liés aux interactions stromales ?\nLes interactions stromales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les tumeurs ?\nLes symptômes sont-ils précoces ou tardifs ?\nLes symptômes sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Finasteride#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Molécules d'interaction stromale",
"description": "Peut-on prévenir les interactions stromales ?\nQuels modes de vie aident à prévenir les tumeurs ?\nLes dépistages réguliers sont-ils utiles ?\nL'éducation sur le cancer est-elle importante ?\nLes vaccins peuvent-ils prévenir les tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Finasteride#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Molécules d'interaction stromale",
"description": "Quels traitements ciblent les molécules stromales ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires des traitements ?\nComment les traitements sont-ils personnalisés ?\nLes traitements sont-ils combinés ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Finasteride#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Molécules d'interaction stromale",
"description": "Quelles complications peuvent survenir ?\nLes interactions stromales aggravent-elles les complications ?\nComment gérer les complications ?\nLes complications sont-elles prévisibles ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Finasteride#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Molécules d'interaction stromale",
"description": "Quels sont les facteurs de risque des interactions stromales ?\nL'alimentation influence-t-elle les risques ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un risque ?",
"url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Finasteride#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une interaction stromale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies et des analyses immunohistochimiques sont utilisées pour évaluer les interactions stromales."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les molécules stromales ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests ELISA et les western blots permettent de quantifier les molécules d'interaction stromale."
}
},
{
"@type": "Question",
"name": "Les marqueurs stromaux sont-ils spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains marqueurs peuvent être spécifiques à des types de tumeurs, mais d'autres sont plus généraux."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les molécules stromales par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques d'imagerie avancées, comme l'IRM, peuvent aider à visualiser les interactions stromales."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet d'obtenir des échantillons pour analyser les interactions stromales au sein des tumeurs."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux interactions stromales ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure douleur, inflammation et signes de progression tumorale."
}
},
{
"@type": "Question",
"name": "Les interactions stromales causent-elles des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent influencer la croissance tumorale et provoquer des symptômes associés."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon les tumeurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de tumeur et de l'environnement stromal spécifique."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils précoces ou tardifs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être précoces ou tardifs, selon la nature de l'interaction stromale."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent s'améliorer avec un traitement ciblant les interactions stromales."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les interactions stromales ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par la réduction des facteurs de risque liés aux tumeurs et à l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels modes de vie aident à prévenir les tumeurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les dépistages peuvent aider à détecter les tumeurs précocement, limitant les interactions stromales."
}
},
{
"@type": "Question",
"name": "L'éducation sur le cancer est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation aide à sensibiliser aux facteurs de risque et aux signes précoces de cancer."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils prévenir les tumeurs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains vaccins, comme ceux contre le HPV, peuvent réduire le risque de cancers associés."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les molécules stromales ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des immunothérapies sont en développement pour cibler ces molécules."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de tumeur et la nature des interactions stromales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires, notamment des réactions immunitaires."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements sont adaptés en fonction du profil moléculaire de la tumeur et de l'environnement stromal."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils combinés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des combinaisons de traitements sont souvent utilisées pour améliorer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la progression tumorale, la résistance au traitement et la métastase."
}
},
{
"@type": "Question",
"name": "Les interactions stromales aggravent-elles les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent favoriser la progression tumorale et compliquer le traitement."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique des traitements ciblés et un suivi régulier pour adapter les thérapies."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être anticipées en fonction du type de tumeur et des interactions."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des interactions stromales ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'inflammation chronique, le tabagisme et des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut réduire les risques d'interactions stromales."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut influencer l'inflammation et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'interactions stromales."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines est-elle un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances toxiques peut favoriser les interactions stromales et le cancer."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 02/04/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca.
Publications dans "Molécules d'interaction stromale" :
3 publications dans cette catégorie
Affiliations :
Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN.
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
Publications dans "Molécules d'interaction stromale" :
3 publications dans cette catégorie
Affiliations :
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.
Publications dans "Molécules d'interaction stromale" :
3 publications dans cette catégorie
Affiliations :
Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Institute of Physiology, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Publications dans "Molécules d'interaction stromale" :
3 publications dans cette catégorie
Affiliations :
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Publications dans "Molécules d'interaction stromale" :
3 publications dans cette catégorie
Affiliations :
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.
Publications dans "Molécules d'interaction stromale" :
3 publications dans cette catégorie
Affiliations :
Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN.
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Biophysics, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2M9, Canada. Electronic address: mikura@uhnresearch.ca.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario N6A5C1, Canada.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Xiamen University, College of Chemistry and Chemical Engineering & Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), CHINA.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Xiamen University, College of Chemistry and Chemical Engineering, Siming south road 422, 3012, Xiamen, CHINA.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Department of Physics, Indiana University Indianapolis, Indianpolis, Indiana, USA.
Publications dans "Molécules d'interaction stromale" :
2 publications dans cette catégorie
Affiliations :
Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana, USA.
Publications dans "Molécules d'interaction stromale" :
1 publication dans cette catégorie
Affiliations :
Universiti Sains Malaysia, Advanced Medical and Dental Institute, Department of Biomedical Science, Pulau Pinang, Malaysia
Hadhramout University, Faculty of Medicine and Health Sciences, Department of Basic Medical Sciences, Hadhramout, Yemen
Publications dans "Molécules d'interaction stromale" :
1 publication dans cette catégorie
Affiliations :
Universiti Sains Malaysia, Advanced Medical and Dental Institute, Department of Biomedical Science, Pulau Pinang, Malaysia
Publications dans "Molécules d'interaction stromale" :
The fundamental purpose of this study was to develop a stable lyophilised finasteride nanosystem (FNS-NS) for topical delivery. The FNS-NS was fabricated using an ultrasonication technique. The impact...
5-alpha reductase inhibitor (5ARI) reduces prostate-specific antigen (PSA) by half but its effect on prostate health index (phi) is unknown. This study aims to investigate this effect and to enable ac...
This is a prospective study evaluating the effect of finasteride on PSA, free PSA (fPSA), [ - 2]proPSA (p2PSA) and phi at 6 and 12 moths in men with PSA 4-20 ng/mL, no prior 5ARI use, and one negative...
164 men fit the inclusion criteria and 150 were analyzed. In 5ARI group (n = 100) at 1 year, mean PSA reduced by 51.4% from 8.9(± SD 3.7) to 4.4(± SD 2.8)ng/mL (paired t-test, p < 0.001), fPSA reduced...
This study demonstrated p2PSA and phi are reduced by about 55% and 34% in men on 5ARI. A conversion factor of division by 0.66 is needed for phi in men on finasteride to allow the interpretation and u...
Androgenetic alopecia (AGA) is the most common cause of hair loss, often challenging to treat. While oral finasteride (1 mg/d) is an FDA-approved treatment for male AGA, oral minoxidil and oral dutast...
A probable efficacy ranking, in decreasing order, is - dutasteride 0.5 mg/d, finasteride 5 mg/d, minoxidil 5 mg/d, finasteride 1 mg/d, followed by minoxidil 0.25 mg/d. Oral minoxidil predominantly cau...
The average plasma half-lives of minoxidil, finasteride, and dutasteride are ∼4 h, ∼4.5 h, and ∼5 weeks, respectively. Minoxidil acts through multiple pathways to promote hair growth. It has been show...
Androgenetic alopecia (AGA) is treated by 5α-reductase inhibitors (5ARI) such as finasteride and dutasteride, which are widely used as therapeutic agents. However, their pharmacokinetics in target org...
To confirm the effective action of finasteride and dutasteride in the hair follicle tissues, we developed a method to measure these concentrations in hair....
Compared to the non-detection (N.D.) group, the dihydrotestosterone (DHT) concentrations decreased significantly in both the finasteride and dutasteride groups. The dutasteride group showed significan...
Measurement of finasteride, dutasteride, and DHT concentrations in hair would aid in evaluating the drug pharmacokinetics and its therapeutic effects on AGA patients....
Finasteride is considered the drug of choice for androgenic alopecia and benign prostate hyperplasia. The aim of the study was to formulate nanodrug carriers of finasteride with enhanced retentive pro...
Gut microbes are closely associated with disease onset and improvement. However, the effects of gut microbes on the occurrence, prevention, and treatment of benign prostatic hyperplasia (BPH) are stil...
Androgen suppression therapy has been associated with a lower incidence of bladder cancer (BCa) or improved overall/cancer-specific survival. Results are ofent conflicting; therefore, we aim to assess...
The South Texas Veterans Healthcare System from 5 medical centers was queried for patients with BCa with or without use of finasteride after diagnosis of BCa. The primary outcome was the impact of fin...
A total of 1890 patients were included, amongst which 619 (32.8%) men were classified as finasteride users and 1271 (67.2%) men as controls. At a median (IQR) follow up of 53.8 (27.4, 90.9) months, de...
Finasteride use is associated with the improved overall survival in patients with BCa, specifically in patients with NMIBC. We, further, propose a randomized clinical trial to investigate the use of f...
Herein, we report nanogels comprising diverse feed ratio of polymer hydroxypropyl methylcellulose (HPMC), monomer acrylic acid (AA), and cross-linker methylene bisacrylamide (MBA) fabricated for trans...
LDOM has enhanced treatment options for female AGA, yet its combined efficacy with therapies such as spironolactone, finasteride, or dutasteride remains inadequately explored. This study aims to compa...
Benign prostatic hyperplasia (BPH) may decrease patient quality of life and often leads to acute urinary retention and surgical intervention. While effective treatments are available, many BPH patient...